Legal and regulatory news kept biotech and pharma stocks somewhat in the green on Thursday.Affymetrix ( AFFX) and Illumina ( ILMN) were both on the move after settling a lawsuit on Thursday. Affymetrix was suing on the premise of patent violation for multiple products after winning $16.7 million on five previous counts of patent infringement in October. The company agreed to drop all claims for a one-time payment of $90 million. Investors indicated Illumina got the better end of the deal, taking Affymetrix shares down $1.26, or 5.3%, to $22.50, and pushing Illumina up $11.67, or 19.3%, to 72.13. Both stocks are components of the Nasdaq biotechnology index, which was up 8.72, or 1%, to 857.71. Various regulatory updates nudged other stocks around. Progenics ( PGNX) shares fell back in morning trading on an FDA delay, but seemingly recovered with investor optimism. The company and its partner Wyeth ( WYE) said Thursday morning that the U.S. Food and Drug Administration pushed back the action date for a review of a new drug application for subcutaneous methylnaltrexone, which is being reviewed for opioid-induced constipation. According to the companies, the agency needs time to review a recent study on QT prolongation and plans to have a review complete by April 30. Lazard analyst Joel Sendek noted in a report on the stock that an FDA panel could follow the extended review. But Sendek, unshaken, also noted, "We continue to believe that sc-MNTX will receive approval for AMI-OIC."